Identification of 13 new mutations in the vasopressin-neurophysin II gene in 17 kindreds with familial autosomal dominant neurohypophyseal diabetes insipidus

S Rittig, G L Robertson, C Siggaard, L Kovács, N Gregersen, J Nyborg, E B Pedersen, S Rittig, G L Robertson, C Siggaard, L Kovács, N Gregersen, J Nyborg, E B Pedersen

Abstract

Familial neurohypophyseal diabetes insipidus (FNDI) is an autosomal dominant disorder characterized by progressive postnatal deficiency of arginine vasopressin as a result of mutation in the gene that encodes the hormone. To determine the extent of mutations in the coding region that produce the phenotype, we studied members of 17 unrelated kindreds with the disorder. We sequenced all 3 exons of the gene by using a rapid, direct dye-terminator method and found the causative mutation in each kindred. In four kindreds, the mutations were each identical to mutations described in other affected families. In the other 13 kindreds each mutation was unique. There were two missense mutations that altered the cleavage region of the signal peptide, seven missense mutations in exon 2, which codes for the conserved portion of the protein, one nonsense mutation in exon 2, and three nonsense mutations in exon 3. These findings, together with the clinical features of FNDI, suggest that each of the mutations exerts an effect by directing the production of a pre-prohormone that cannot be folded, processed, or degraded properly and eventually destroys vasopressinergic neurons.

References

    1. J Clin Invest. 1993 Jun;91(6):2565-71
    1. J Clin Endocrinol Metab. 1993 Sep;77(3):600-4
    1. J Biol Chem. 1990 Feb 25;265(6):3417-23
    1. J Cell Biol. 1988 Apr;106(4):1035-42
    1. J Pediatr. 1982 Jan;100(1):76-81
    1. Q J Med. 1959 Oct;28:573-82
    1. Clin Chim Acta. 1991 Nov 9;203(1):23-34
    1. Acta Med Scand. 1985;217(4):429-34
    1. Experientia. 1992 Feb 15;48(2):118-29
    1. J Clin Invest. 1991 Feb;87(2):725-8
    1. J Biol Chem. 1985 Aug 25;260(18):10236-41
    1. Postgrad Med J. 1981 Jan;57(663):36-40
    1. Eur J Biochem. 1994 Jan 15;219(1-2):11-23
    1. Folia Med Neerl. 1970;13(2):68-72
    1. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9014-8
    1. Trends Biochem Sci. 1992 Nov;17(11):474-8
    1. Eur J Clin Pharmacol. 1984;26(5):543-7
    1. Can Med Assoc J. 1984 Nov 15;131(10):1237-41
    1. EMBO J. 1992 Jan;11(1):19-23
    1. Nature. 1982 Jan 28;295(5847):299-303
    1. J Biol Chem. 1993 Mar 5;268(7):5201-8
    1. J Biol Chem. 1990 Oct 5;265(28):17202-8
    1. J Cell Biol. 1992 May;117(3):505-13
    1. FEBS Lett. 1992 Nov 2;312(1):83-6
    1. Trends Cell Biol. 1992 Aug;2(8):227-31
    1. J Clin Invest. 1973 Sep;52(9):2340-52
    1. FEBS Lett. 1988 Oct 10;238(2):329-32
    1. J Clin Endocrinol Metab. 1994 Aug;79(2):421-7
    1. J Mol Biol. 1984 Feb 25;173(2):243-51
    1. Ann Intern Med. 1965 Sep;63:503-8
    1. Pediatrics. 1953 Mar;11(3):246-54
    1. J Clin Endocrinol Metab. 1995 Apr;80(4):1352-6
    1. Cell. 1981 May;24(2):453-61
    1. J Biol Chem. 1991 Jan 15;266(2):1326-34
    1. J Clin Endocrinol Metab. 1955 May;15(5):547-52
    1. Am J Med Sci. 1983 Nov-Dec;286(3):42-6
    1. Can Med Assoc J. 1973 Oct 6;109(7):594-7
    1. Brain. 1967 Sep;90(3):707-14
    1. Somat Cell Mol Genet. 1985 Mar;11(2):189-95
    1. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4240-4
    1. Biochem J. 1994 Apr 1;299 ( Pt 1):1-18
    1. Semin Nephrol. 1994 Jul;14(4):368-83
    1. Trends Biochem Sci. 1994 Apr;19(4):176-81
    1. Q J Med. 1985 Dec;57(224):883-96
    1. J Biol Chem. 1988 Feb 5;263(4):2070-8
    1. J Clin Endocrinol Metab. 1993 Sep;77(3):599A-599G
    1. J Genet Hum. 1955 Dec;4(4):195-203
    1. Biochem J. 1990 Aug 1;269(3):691-6
    1. Klin Wochenschr. 1981 Aug 3;59(15):831-6
    1. Curr Opin Cell Biol. 1993 Aug;5(4):589-95
    1. Hum Mutat. 1994;4(2):102-13
    1. Cell. 1994 Dec 30;79(7):1129-32
    1. FEBS Lett. 1985 Nov 25;193(1):12-6

Source: PubMed

3
구독하다